SOURCE: OctoPlus N.V.

OctoPlus N.V.

March 23, 2011 03:28 ET

OctoPlus Publishes Annual Report 2010

LEIDEN, THE NETHERLANDS--(Marketwire - March 23, 2011) - OctoPlus N.V. ("OctoPlus" or the "Company") (AMS: OCTO) announces today the publication of its Annual Report 2010. The Annual Report is now available on the Company's website, www.octoplus.nl.

During 2010, successful clinical Phase IIb results for Locteron® were presented, which further validated the potential of our PolyActive® technology. In addition to Locteron, we are building a portfolio of compounds utilising our proprietary controlled release technologies.

Key events during 2010 were:

  • Jan Egberts joined OctoPlus in November 2010 and formally started as CEO on 1 January 2011
  • Non-Locteron revenues grew by 18% in the second half-year compared to the first half-year of 2010
  • We realised a significantly reduced cost base and completed a successful financing.

About OctoPlus
OctoPlus is a drug delivery service company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.

The clinically most advanced product incorporating our technology is Biolex Therapeutics' lead product Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and has recently completed Phase IIb clinical studies with superior clinical data versus current treatment.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect," "anticipate," "predict," "estimate," "project," "plan," "may," "should," "would," "will," "intend," "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

Contact Information

  • For further information, please contact:
    Rianne Roukema
    Corporate Communications
    Telephone number +31 (71) 524 1071
    Investor Relations
    IR@octoplus.nl